Update on the therapeutic approaches to brain tumors

Expert Review of Anticancer Therapy

Volumn 3, Issue 5, 2003, Pages 655-670

  Lallana, Enrico C ^a   Abrey, Lauren E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Astrocytoma; Biologic agent; Brain tumor; Chemotherapy; Meningioma; Oligodendroglioma; PCNSL; Radiotherapy; Surgery

Indexed keywords

ALPHA2B INTERFERON; ANTIBODY; CARBOPLATIN; CARMUSTINE; CHIMERIC PROTEIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE; DEXAMETHASONE; DIAZIQUONE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; HYDROXYUREA; LOMUSTINE; LONAFARNIB; METHOTREXATE; MICROSPHERE; MIFEPRISTONE; NIMUSTINE; PLATINUM DERIVATIVE; POLYMER; PREDNISONE; PROCARBAZINE; TAMOXIFEN; TEMOZOLOMIDE; TRANSFERRIN; UNINDEXED DRUG; VINCRISTINE;

ADOLESCENT; ADULT; ASTROCYTOMA; BIODEGRADABLE IMPLANT; BRAIN LYMPHOMA; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; GENETICS; GLIOMA; HUMAN; INFECTION; INTRACRANIAL HYPERTENSION; MENINGIOMA; MOLECULAR BIOLOGY; NEUROTOXICITY; NEUTRON CAPTURE THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIOMA; REVIEW; SAFETY; SCHOOL CHILD; TUMOR BIOPSY; TUMOR LOCALIZATION; TUMOR VOLUME; WOUND HEALING;

EID: 0242350982     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.5.655     Document Type: Review

References (139)

1. Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1995-1999. Central Brain Tumor Registry of the United States, IL, USA (2002).
2. Preul MC, Caramanos Z, Collins DL et al. Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nature Med. 2(3), 323-325 (1996).
3. Tamiya T, Kinoshita K, Ono Y, Matsumoto K, Furuta T, Ohmoto T. Proton magnetic resonance spectroscopy reflects cellular proliferative activity in astrocytomas. Neuroradiology 42(5), 333-338 (2000).
4. Jackson RJ, Fuller GN, Abi-Said D et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neurooncology 3(3), 193-200 (2001).
5. Berger MS, Deliganis AV, Dobbins J, Keles GE. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 74(6), 1784-1791 (1994).
6. Kilic T, Ozduman K, Elmaci I et al. Effect of surgery on tumor progression and malignant degeneration in hemispheric diffuse low-grade astrocytomas. J. Clin. Neurosci. 9(5), 549-552 (2002).
7. Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Ann. Neurol. 31(4), 431-436 (1992).
8. Harbaugh KS, Black PM. Strategies in the surgical management of malignant gliomas. Semin. Surg. Oncol. 14(1), 26-33 (1998).
9. Karim AB, Maat B, Hatlevoll R et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int. J. Radiat. Oncol. Biol. Phys. 36(3), 549-556 (1996).
10. Shaw E, Arusell R, Scheithauer B et al. Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Co-operative Oncology Group study. J. Clin. Oncol. 20(9), 2267-2276 (2002).
11. Karim AB, Afra D, Cornu P et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int. J. Radiat. Oncol. Biol. Phys. 52(2), 316-324 (2002).
12. Friedman HS, Krischer JP, Burger P et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized Phase II study. J. Clin. Oncol. 10(2), 249-256 (1992).
13. Packer RJ, Ater J, Allen J et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J. Neurosurg. 86(5), 747-754 (1997).
14. Castello MA, Schiavetti A, Varrasso G, Clerico A, Cappelli C. Chemotherapy in low-grade astrocytoma management. Childs Nerv. Syst. 14(1-2), 6-9 (1998).
15. Eyre HJ, Crowley JJ, Townsend JJ et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J. Neurosurg. 78(6), 909-914 (1993).
16. Quinn JA, Reardon DA, Friedman AH et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J. Clin. Oncol. 21(4), 646-651 (2003).
17. Viviers L, Brada M, Hines F, Britton J, Abson C, Ashley S. A Phase II trial of primary chemotherapy with temozolomide in patients with low-grade cerebral gliomas. Proc. Am. Soc. Clin. Oncol. (2000) (Abstract 648).
18. Ciric I, Ammirati M, Vick N, Mikhael M. Supratentorial gliomas: surgical considerations and immediate postoperative results. Gross total resection versus partial resection. Neurosurgery 21 (1), 21-26 (1987).
19. Ammirati M, Vick N, Liao YL, Ciric I, Mikhael M. Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery 21(2), 201-206 (1987).
20. Simpson JR, Horton J, Scott C et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int. J. Radiat. Oncol. Biol. Phys. 26(2), 239-244 (1993).
21. Coffey RJ, Lunsford LD, Taylor FH. Survival after stereotactic biopsy of malignant gliomas. Neurosurgery 22(3), 465-473 (1988).
22. Andersen AP. Postoperative irradiation of glioblastomas. Results in a randomized series. Acta Radiol. Oncol. Radiat. Phys. Biol. 17(6), 475-484 (1978).
23. Walker MD, Alexander E Jr, Hunt WE et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A co-operative clinical trial. J. Neurosurg. 49(3), 333-343 (1978).
24. Walker MD, Green SB, Byar DP et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med. 303(23), 1323-1329 (1980).
25. DeAngelis LM, Burger PC, Green SB, Cairncross JG. Malignant glioma: who benefits from adjuvant chemotherapy? Ann. Neurol. 44(4), 691-695 (1998).
26. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71(8), 2585-2597 (1993).
27. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359(9311), 1011-1018 (2002).
28. Yung WK, Prados MD, Yaya-Tur R et al. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol. 17(9), 2762-2771 (1999).
29. Yung WK, Albright RE, Olson J et al. A Phase II study of temozolomide versus procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer 83(5), 588-593 (2000).
30. Stupp R, Dietrich PY, Ostermann Kraljevic S et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol. 20(5), 1375-1382 (2002).
31. Lee YY, Van Tassel P. Intracranial oligodendrogliomas: imaging findings in 35 untreated cases. AJR Am. J. Roentgenol. 152(2), 361-369 (1989).
32. Ino Y, Betensky R, Zlatescu M et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin. Cancer Res. 7(4), 839-845 (2001).
33. Buckner JC, Gesme D Jr, O'Fallon JR et al. Phase II trial of procarbazine, lomustine and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J. Clin. Oncol. 21(2), 251-225 (2003).
34. Bullard DE, Rawlings CE III, Phillips B et al. Oligodendroglioma. An analysis of the value of radiation therapy. Cancer 60(9), 2179-2188 (1987).
35. Nijjar TS, Simpson WJ, Gadalla T, McCartney M. Oligodendroglioma. The Princess Margaret Hospital experience (1958-1984). Cancer 71(12), 4002-4006 (1993).
36. Kros JM, Pieterman H, van Eden CG, Avezaat CJ. Oligodendroglioma: the Rotterdam-Dijkzigt experience. Neurosurgery 34(6), 959-966 (1994).
37. Wallner KE, Gonzales M, Sheline GE. Treatment of oligodendrogliomas with or without postoperative irradiation. J. Neurosurg. 68(5), 684-688 (1988).
38. Shimizu KT, Tran LM, Mark RJ, Selch MT. Management of oligodendrogliomas. Radiology 186(2), 569-572 (1993).
39. Gannett DE, Wisbeck WM, Silbergeld DL, Berger MS. The role of postoperative irradiation in the treatment of oligodendroglioma. Int. J. Radiat. Oncol. Biol. Phys. 30(3), 567-573 (1994).
40. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis DH. Oligodendrogliomas: the Mayo Clinic experience. J. Neurosurg. 76(3), 428-434 (1992).
41. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann. Neurol. 23(4), 360-364 (1988).
42. Cairncross G, Macdonald D, Ludwin S et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 12(10), 2013-2021 (1994).
43. Paleologos NA, Macdonald DR, Vick NA, Cairncross JG. Neoadjuvant procarbazine, CCNU and vincristine for anaplastic and aggressive oligodendroglioma. Neurolgy 53(5), 1141-1143 (1999).
44. Chinot OL, Honore S, Dufour H et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J. Clin. Oncol. 19(9), 2449-2455 (2001).
45. Van Den Bent MJ, Chinot O, Boogerd W et al. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group Phase II study 26972. Ann. Oncol. 14(4), 599-602 (2003).
46. Van den Bent MJ, Taphoorn MJ, Brandes AA et al. European Organization for Research and Treatment of Cancer Brain Tumor Group. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J. Clin. Oncol. 21 (13), 2525-2528 (2003).
47. Brandes AA, Basso U, Vastola F et al. First line chemotherapy with temozolomide in recurrent or progressive oligodendroglioma. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 426).
48. Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with PCV chemotherapy. Neurolgy 51(4), 1140-1145 (1998).
49. Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL. Meningioma: analysis of recurrence and progression following neurosurgical resection. J. Neurosurg. 62(1), 18-24 (1985).
50. Melamed S, Sahar A, Beller AJ. The recurrence of intracranial meningiomas. Neurochirurgia (Stuttg) 22(2), 47-51 (1979).
51. Goldsmith BJ, Wara WM, Wilson CB, Larson DA. Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J. Neurosurg. 80(2), 195-201 (1994). Erratum in J. Neurosurg. 80(4), 777 (1994).
52. Miralbell R, Linggood RM, de la Monte S, Convery K, Munzenrider JE, Mirimanoff RO. The role of radiotherapy in the treatment of subtotally resected benign meningiomas. J. Neurooncol. 13(2), 157-164 (1992).
53. Maire JP, Caudry M, Guerin J et al. Fractionated radiation therapy in the treatment of intracranial meningiomas: local control, functional efficacy and tolerance in 91 patients. Int. J. Radiat. Oncol. Biol. Phys. 33(2), 315-321 (1995).
54. Hug EB, Devries A, Thornton AF et al. Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy. J. Neurooncol. 48(2), 151-160 (2000).
55. Kondziolka D, Lunsford LD, Coffey RJ, Flickinger JC. Stereotactic radiosurgery of meningiomas. J. Neurosurg. 74(4), 552-559 (1991).
56. Subach BR, Lunsford LD, Kondziolka D, Maitz AH, Flickinger JC. Management of petroclival meningiomas by stereotactic radiosurgery. Neurosurgery 42(3), 437-443 (1998).
57. Roche PH, Regis J, Dufour H et al. Gamma knife radiosurgery in the management of cavernous sinus meningiomas. J. Neurosurg. 93(Suppl. 3), 68-73 (2000).
58. Chamberlain MC. Adjuvant combined modality therapy for malignant meningiomas. J. Neurosurg. 84(5), 733-736 (1996).
59. Schrell UM, Rittig MG, Anders M et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J. Neurosurg. 86(5), 840-844 (1997).
60. Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J. Neurosurg. 97(2), 341-346 (2002).
61. Goodwin JW, Crowley J, Eyre HJ, Stafford B, Jaeckle KA, Townsend JJ. A Phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J. Neurooncol. 15(1), 75-77 (1993).
62. Kaba SE, DeMonte F, Bruner JM et al. The treatment of recurrent unresectable and malignant meningiomas with interferon α-2B. Neurosurgery 40(2), 271-275 (1997).
63. Grunberg SM, Weiss MH, Spitz IM et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J. Neurosurg. 74(6), 861-866 (1991).
64. Cote TR, Manns A, Hardy CR, Yellin FJ, Hartge P. Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group. J. Natl Cancer Inst. 88(10), 675-679 (1996).
65. Herrlinger U. Primary CNS lymphoma: findings outside the brain. J. Neurooncol. 43(3), 227-230 (1999).
66. Henry JM, Heffner RR Jr, Dillard SH, Earle EM, Davis RL. Primary malignant lymphomas of the central nervous system. Cancer 34(4), 1293-1302 (1974).
67. Nelson DF, Martz KL, Bonner H et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int. J. Radiat. Oncol. Biol. Phys. 23(1), 9-17 (1992).
68. Gabbai AA, Hochberg FH, Linggood RM, Bashir R, Hotleman K. High-dose methotrexate for non-AIDS primary central nervous system lymphoma. Report of 13 cases. J. Neurosurg. 70(2), 190-194 (1989).
69. Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J. Neurosurg. 81(2), 188-195 (1994).
70. McAllister LD, Doolittle ND, Guastadisegni PE et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46(1), 51-60 (2000).
71. DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J. Clin. Oncol. 10(4), 635-643 (1992).
72. Sandor V, Stark-Vancs V, Pearson D et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J. Clin. Oncol. 16(9), 3000-3006 (1998).
73. Cheng AL, Yeh KH, Uen WC, Hung RL, Liu MY, Wang CH. Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma: a pilot study of the BOMES protocol. Cancer 82(10), 1946-1951 (1998).
74. Cher L, Glass J, Harsh GR, Hochberg FH. Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results. Neurology 46(6), 1757-1759 (1996).
75. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J. Clin. Oncol. 18(17), 3144-3150 (2000).
76. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Radiation Therapy Oncology Group Study 93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma. J. Clin. Oncol. 20(24), 4643-4648 (2002).
77. Batchelor T, Carson K, O'Neill A et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J. Clin. Oncol. 21(6), 1044-1049 (2003).
78. Brem H, Ewend MG, Piantadosi S, Greenhoot J, Burger PC, Sisti M. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: Phase I trial. J. Neurooncol. 26(2), 111-123 (1995).
79. Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer Brain Tumor Treatment Group. Lancet 345(8956), 1008-1012 (1995).
80. Westphal M, Hilt DC, Bortey E et al. A Phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neurooncology 5(2), 79-88 (2003).
81. Subach BR, Witham TF, Kondziolka D, Lunsford LD, Bozik M, Schiff D. Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. Neurosurgery 45(1), 17-22 (1999).
82. McGovern PC, Lautenbach E, Brennan PJ, Lustig RA, Fishman NO. Risk factors for postcraniotomy surgical site infection after 1,3-bis(2-chloroethyl)-1-nitrosourea (Gliadel) wafer placement. Clin. Infect. Dis. 36(6), 759-765 (2003).
83. Engelhard HH. Tumor bed cyst formation after BCNU wafer implantation: report of two cases. Surg. Neurol. 53(3), 220-224 (2000).
84. Veziers J, Lesourd M, Jollivet C, Montero-Menei C, Benoit JP, Menei P. Analysis of brain biocompatibility of drug-releasing biodegradable microspheres by scanning and transmission electron microscopy. J. Neurosurg. 95(3), 489-494 (2001).
85. Fournier E, Passirani C, Montero-Menei C et al. Therapeutic effectiveness of novel 5-fluorouracil-loaded poly(methylidene malonate 2.1.2)-based microspheres on F98 glioma-bearing rats. Cancer 97(11), 2822-2829 (2003).
86. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. USA 91(6), 2076-2080 (1994).
87. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nature Med. 3(12), 1362-1368 (1997).
88. Wakabayashi T, Yoshida J, Mizuno M, Kajita Y. Intratumoral microinfusion of nimustine (ACNU) for recurrent glioma. Brain Tumor Pathol. 18(1), 23-28 (2001).
89. Debinski W, Obiri NI, Pastan I, Puri RK. A novel chimeric protein composed of interleukin-13 and pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin-13 and interleukin-4. J. Biol. Chem. 270(28), 16775-16780 (1995).
90. Debinski W, Gibo DM, Slagle B, Powers SK, Gillespie GY. Receptor for interleukin-13 is abundantly and specifically overexpressed in patients with glioblastoma multiforme. Int. J. Oncol. 15(3), 481-486 (1999).
91. Husain SR, Joshi BH, Puri RK. Interleukin-13 receptor as a unique target for antiglioblastoma therapy. Int. J. Cancer 92(2), 168-175 (2001).
92. Weingart J, Markert J, Rosenblum M et al. Determination of toxicities and maximum tolerated dose (MTD) of intra-tumoral infusion of IL13-PE38QQR cytotoxin in patients with recurrent supratentorial malignant glioma: a Phase I/II study. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 405).
93. Ram Z, Barnett G, Vogelbaum S et al. Pre-operative infusion of IL13-PE38QQR cytotoxin by convection-enhanced delivery in recurrent malignant glioma: a Phase I/II study. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 403).
94. Kunwar S, Prados M, Lang F et al. Pre- and post-operative infusion of IL13PE38QQR cytotoxin by convection-enhanced delivery (CED) in recurrent malignant glioma: a Phase I study. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 476).
95. Uy NW, Woo SY, Teh BS et al. Intensity-modulated radiation therapy (IMRT) for meningioma. Int. J. Radiat. Oncol. Biol. Phys. 53(5), 1265-1270 (2002).
96. Pirzkall A, Debus J, Haering P et al. Intensity modulated radiotherapy (IMRT) for recurrent, residual, or untreated skull-base meningiomas: preliminary clinical experience. Int. J. Radiat. Oncol. Biol. Phys. 55(2), 362-372 (2003).
97. Voynov G, Kaufmari S, Hong T et al. Treatment of recurrent malignant glioma with stereotactically guided intensity modulated radiation therapy. Am. J. Clin. Oncol. 25(6), 606-611 (2002).
98. Stadler B, Karcher KH, Kogelnik HD, Szepesi T. Misonidazole and irradiation in the treatment of high-grade astrocytomas: further report of the Vienna Study Group. Int. J. Radiat. Oncol. Biol. Phys. 10(9), 1713-1717 (1984).
99. Shin KH, Urtasun RC, Fulton D et al. Multiple daily fractionated radiation therapy and misonidazole in the management of malignant astrocytoma. A preliminary report. Cancer 56(4), 758-760 (1985).
100. Bleehen NM, Wiltshire CR, Plowman PN et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4 cerebral astrocytoma. Br. J. Cancer 43(4), 436-442 (1981).
101. Del Rowe J, Scott C, Werner-Wasik M et al. Single-arm, open-label Phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J. Clin. Oncol. 18(6), 1254-1259 (2000).
102. Kleinberg L, Grossman SA, Piantadosi S et al. Phase I trial to determine the safety, pharmacodynamics and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 17(8), 2593-2603 (1999).
103. Kleinberg L, Grossman SA, Carson K et al. Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a Phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study. J. Clin. Oncol. 20(14), 3149-3155 (2002).
104. Miller RA, Woodburn K, Fan Q et al. In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int. J. Radiat. Oncol. Biol. Phys. 45(4), 981-989 (1999).
105. Xu S, Zakian K, Thaler H et al. Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity. Int. J. Radiat. Oncol. Biol. Phys. 49(5), 1381-1390 (2001).
106. Mehta MP, Rodrigus P, Terhaard CH et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J. Clin. Oncol. 21(13), 2529-2536 (2003).
107. Diaz AZ. Assessment of the results from the Phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician's point of view. J. Neurooncol. 62(1-2), 101-109 (2003).
108. Busse PM, Harling OK, Palmer MR et al. A critical examination of the results from the Harvard-MIT NCT program Phase I clinical trial of neutron capture therapy for intracranial disease. J. Neurooncol. 62(1-2), 111-121 (2003).
109. Holland EC. Gliomagenesis: generic alterations and mouse models. Nature Rev. Genet. 2(2), 120-129 (2001).
110. Sano T, Lin H, Chen X et al. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res. 59(8), 1820-1824 (1999).
111. Guha A, Dashner K, Black PM, Wagner JA, Stiles CD. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int. J. Cancer 60(2), 168-173 (1995).
112. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med. 2(5), 561-566 (1996).
113. Kantarjian H, Sawyers C, Hochhaus A et al. International STI571 CML study group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346(9), 645-652 (2002). Erratum in: N. Engl. J. Med. 346(24), 1923 (2002).
114. Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase II study. Blood 99(6), 1928-1937 (2002).
115. Kilic T, Alberta JA, Zdunek PR et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally-active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 60(18), 5143-5150 (2000).
116. Heimberger AB, Learn CA, Archer GE et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa). Clin. Cancer Res. 8 (11), 3496-3502 (2002).
117. Wakeling AE, Guy SP, Woodburn JR et al. ZD1839 (Iressa): an orally-active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62(20), 5749-5754 (2002).
118. Grunwald V, Hidalgo M. Development of the epidermal growth factor receptor inhibitor OSI-774. Semin. Oncol. 30(3 Suppl. 6), 23-31 (2003).
119. Prados M, Chang S, Burton E. Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 394).
120. Lieberman FS, Cloughesy T, Malkin M et al. Phase I-II study of ZD-1839 for recurrent malignant gliomas and meningiomas progressing after radiation therapy. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 421).
121. Peery TS, Reardon DA, Quinn J et al. Phase II trial of ZD1839 for patients with first relapse glioblastoma. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 396).
122. Sepp-Lorenzino L, Ma Z, Rands E et al. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. 55(22), 5302-5309 (1995).
123. Adjei AA, Erlichman C, Davis JN et al. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. 60(7), 1871-1877 (2000).
124. Metcalfe SM, Canman CE, Milner J, Morris RE, Goldman S, Kastan MB. Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells. Oncogene 15(14), 1635-4642 (1997).
125. Geoerger B, Kerr K, Tang CB et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res. 61(4), 1527-1532 (2001).
126. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA 91(9), 4082-4085 (1994).
127. Fine HA, Wen PY, Maher EA et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J. Clin. Oncol. 21(12), 2299-2304 (2003).
128. Fine HA, Kim L, Royce C et al. A Phase I trial of CC-5103, a potent thalidomide analogue, in patients with recurrent high grade gliomas and other refractory CNS malignancies. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 418).
129. Yung WK, Friedman H, Conrad C. et al. A Phase I trial of single-agent PTK787/ZK 222584 (PTK/ZK) an oral VEGF tyrosine kinase inhibitor, in patients with recurrent glioblastoma multiforme. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 395).
130. Reardon D, Friedman HS, Yung WK et al. A Phase I trial of PTK787/ZK 222584 (PTK/ZK), an oral VEGF tyrosine kinase inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 412)
131. O'Reilly MS, Holmgren L, Shing Y et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79(2), 315-328 (1994).
132. O'Reilly MS, Boehm T, Shing Y et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (2), 277-285 (1997).
133. Kirsch M, Strasser J, Allende R, Bello L, Zhang J, Black PM. Angiostatin suppresses malignant glioma growth in vivo. Cancer Res. 58(20), 4654-4659 (1998).
134. Peroulis I, Jonas N, Saleh M. Anti-angiogenic activity of endostatin inhibits C6 glioma growth. Int. J. Cancer 97(6), 839-845 (2002).
135. Read TA, Sorensen DR, Mahesparan R et al. Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nature Biotechnol. 19(1), 29-34 (2001).
136. Bendandi M, Longo DL. Biologic therapy for lymphoma. Curr. Opin. Oncol. 11 (5), 343-350 (1999).
137. Pels H, Schulz H, Manzke O, Hom E, Thall A, Engert A. Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J. Neurooncol. 59(3), 213-216 (2002).
138. Kaminski MS, Zelenetz AD, Press OW et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol. 19(19), 3918-3928 (2001).
139. Witzig TE, Flinn IW, Gordon LI et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J. Clin. Oncol. 20(15), 3262-3269 (2002).